Jump to Main Content
Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease B Biointerfaces
- Shao, Mei, Hussain, Zahid, Thu, Hnin Ei, Khan, Shahzeb, Katas, Haliza, Ahmed, Tarek A., Tripathy, Minaketan, Leng, Jing, Qin, Hua-Li, Bukhari, Syed Nasir Abbas
- Colloids and surfaces 2016 v.147 pp. 475-491
- T-lymphocytes, allergens, atopic dermatitis, disease control, drugs, education programs, hydrocolloids, immunoglobulin E, lipids, mast cells, nanocarriers, nanoemulsions, nanoparticles, pruritus, psychological stress, sleep deprivation
- Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD.